10mg blend · lyophilized · single vial
4.7(808 researcher reviews)The classic injury-recovery duo, pre-blended.
For research and educational use only. Not for human consumption. Consult a licensed provider before use.
A 1:1 research blend of the two most-studied repair peptides. BPC-157 acts locally on tendons, gut and vasculature; TB-500 works systemically through actin sequestration and cell migration. Together they cover both local and global recovery axes in a single vial.
Every KINETYX vial is filled in a controlled cleanroom and sealed with tamper-evident packaging. Batch documentation includes identity confirmation, HPLC purity analysis and concentration verification.
Curated from public preclinical literature. All content is educational.
This is a 1:1 pre-blended combination of the two most-studied recovery peptides in research: BPC-157 (Body Protection Compound-157) and TB-500 (a fragment of Thymosin Beta-4).
Researchers often reach for this stack because the two peptides target different but complementary mechanisms of tissue repair — one predominantly local, one predominantly systemic — in a single administration.
BPC-157 drives angiogenesis (VEGFR2), fibroblast migration (FAK/paxillin) and nitric-oxide modulation at the site of injection or injury.
TB-500 sequesters G-actin, enabling cell migration and recruitment of repair cells throughout the body via the circulation.
The combined effect is a broader recovery signal than either peptide alone: local tissue rebuilding plus systemic cell trafficking.
• Faster tendon and ligament recovery in animal models
• Improved capillary density around injury sites
• Anti-inflammatory activity at both local and systemic scales
• Widely favored blend in preclinical soft-tissue repair research
Common research protocol: 500 mcg blend, once daily subcutaneously, 4–6 weeks loading phase.
1 vial = 10 mg total blend (5 mg BPC-157 + 5 mg TB-500).
Generally well tolerated.
Occasional mild injection-site sensitivity.
For in-vitro research use only. Not for human or veterinary consumption.
Enter the bacteriostatic water volume you'll add and the target dose. We'll compute the units on a standard U-100 insulin syringe.
Reference only. Assumes U-100 syringe (100 units = 1 mL). Not medical advice.
Common research protocol: 500 mcg blend, once daily subcutaneously, 4–6 weeks loading phase.
1 vial = 10 mg total blend (5 mg BPC-157 + 5 mg TB-500).
Refrigerate reconstituted vial at 2–8°C. Use within 30 days. Lyophilized vials stable ≥12 months at −20°C.
Yes. Every batch of BPC-157 + TB-500 ships with an HPLC purity report and identity confirmation from an independent lab. Batch numbers are searchable in our Lab Results portal.
Ambient, insulated mailer, discreet plain packaging. Includes BAC water + 12 syringes. Domestic delivery in 24–48h.
Currently US only for research supply. International researcher accounts require verification.
Lyophilized vials remain stable for 12+ months at −20°C. Once reconstituted, refrigerate at 2–8°C and use within 30 days.
Orders placed by 2pm ET ship same day.
Overnight or 2-day, tracked, ambient shipping.
Orders over $150 ship free within the US.
Unopened vials returnable within 14 days. Batch-verified refunds always honored.
Compared this side by side with two other suppliers. KINETYX was the only one that documented concentration verification.
Been running a conservative research protocol for four weeks. Response curve is consistent with published literature.
Compared this side by side with two other suppliers. KINETYX was the only one that documented concentration verification.
Been running a conservative research protocol for four weeks. Response curve is consistent with published literature.